2045 - The analysis of treatment sequences and clinical outcomes of thymic carcinoma

Background

Thymic carcinoma is one of the rare cancers with a poor prognosis if unresectable. There is no standard chemotherapy for thymic carcinoma since there are only single arm trials or small number of retrospective studies. Here, we retrospectively assessed the effectiveness of chemotherapy for thymic carcinoma treated at the National Cancer Center Hospital Japan.

Methods

Eligible patients had unresectable advanced thymic carcinoma and were treated with chemotherapy between January 2006 and March 2019. We assessed the overall survival (OS), progression-free survival (PFS), and the response rate (RR). OS and PFS were assessed from the start of each treatment line, and of chemotherapy regimen, respectively.

Results

The total number of the subject was 79. As a first line chemotherapy, 72 patients were treated with carboplatin and paclitaxel (CbPx), and the others were treated with S-1 (n = 1), docetaxel (n = 1), and investigational drug (n = 2). Median PFS (mPFS) was 6.2 months and OS (mOS) was 38.9 months. Among 53 patients who received 2^ndline chemotherapy, 31 patients received S-1, 5 patients received sunitinib, 3 patients received CbPx, with mPFS of 5.7 months, and mOS of 23.4 months. Among 36 patients who received 3^rdline chemotherapy, 15 patients received sunitinib and 7 patients received S-1 with mPFS of 3.0 months, and mOS of 14.0 months. RR and mPFS of each regimens were as follows: CbPx (n = 76) 36.8%, 6.2 months, S-1 (n = 44) 25.0%, 4.1 months, and sunitinib (n = 28) 21.4%, 3.4 months.

Conclusions

This is the largest reported single institute retrospective experience of patients with advanced thymic carcinoma. The efficacy of commonly used chemotherapies was confirmed.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

Y. Goto: Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (institution): Eli Lilly; Advisory / Consultancy, Speaker Bureau / Expert testimony: Chugai; Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (institution): Taiho Pharmaceutical; Advisory / Consultancy, Speaker Bureau / Expert testimony: Boehringer Ingelheim; Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (institution): Pfizer; Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (institution): Novartis; Advisory / Consultancy, Speaker Bureau / Expert testimony: AstraZeneca; Advisory / Consultancy: Glaxo Smith Kline; Advisory / Consultancy, Speaker Bureau / Expert testimony: MSD; Advisory / Consultancy: Guardant Health ; Speaker Bureau / Expert testimony, Research grant / Funding (institution): Ono Pharmaceutical; Speaker Bureau / Expert testimony, Research grant / Funding (institution): Bristol Myers Squibb; Speaker Bureau / Expert testimony: Shionogi Pharma; Research grant / Funding (institution): Abbvie; Research grant / Funding (institution): Daiichi Sankyo; Research grant / Funding (institution): Kyorin. S. Kanda: Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): AstraZeneca; Honoraria (self), Research grant / Funding (institution): Ono Pharmaceutical; Honoraria (self): BMS; Honoraria (self): Chugai; Honoraria (self): MSD. H. Horinouchi: Advisory / Consultancy, Speaker Bureau / Expert testimony: Eli Lilly; Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (institution): Chugai; Advisory / Consultancy: Boehringer Ingelheim; Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (institution): Novartis; Advisory / Consultancy, Speaker Bureau / Expert testimony: AstraZeneca; Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (institution): MSD; Speaker Bureau / Expert testimony, Research grant / Funding (institution): Taiho Pharmaceutical; Speaker Bureau / Expert testimony, Research grant / Funding (institution): Ono Pharmaceutical; Speaker Bureau / Expert testimony, Research grant / Funding (institution): Bristol Myers Squibb; Speaker Bureau / Expert testimony: Kyowa-kirin; Research grant / Funding (institution): Abbvie; Research grant / Funding (institution): Daiichi Sankyo; Research grant / Funding (institution): Kyorin; Research grant / Funding (institution): Genomic Health. N. Yamamoto: Research grant / Funding (institution): Astellas; Speaker Bureau / Expert testimony, Research grant / Funding (institution): Chugai; Advisory / Consultancy, Research grant / Funding (institution): Eisai; Research grant / Funding (institution): Taiho; Speaker Bureau / Expert testimony, Research grant / Funding (institution): BMS; Speaker Bureau / Expert testimony, Research grant / Funding (institution): Pfizer; Research grant / Funding (institution): Novartis; Speaker Bureau / Expert testimony, Research grant / Funding (institution): Eli Lilly; Research grant / Funding (institution): AbbVie; Research grant / Funding (institution): Daiichi Sankyo; Research grant / Funding (institution): Bayer; Advisory / Consultancy, Research grant / Funding (institution): Boehringer Ingelheim; Research grant / Funding (institution): Kyowa-Hakko Kirin; Advisory / Consultancy, Research grant / Funding (institution): Takeda; Speaker Bureau / Expert testimony, Research grant / Funding (institution): Ono; Research grant / Funding (institution): Janssen Pharma; Research grant / Funding (institution): MSD; Research grant / Funding (institution): Merck; Advisory / Consultancy: Otsuka; Advisory / Consultancy: Cimic. Y. Ohe: Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): AstraZeneca; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Chugai; Honoraria (self), Research grant / Funding (institution): Lilly; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Ono; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Bristol-Myers Squibb; Honoraria (self): Boehringer Ingelheim; Honoraria (self): Bayer; Honoraria (self), Research grant / Funding (institution): Pfizer; Honoraria (self): MSD; Honoraria (self), Research grant / Funding (institution): Taiho; Advisory / Consultancy, Research grant / Funding (institution): Kyorin; Advisory / Consultancy: Celltrion; Advisory / Consultancy: Amgen; Research grant / Funding (institution): Dainippon Sumitomo; Research grant / Funding (institution): Novartis; Research grant / Funding (institution): Ignyta; Research grant / Funding (institution): Takeda; Research grant / Funding (institution): Kissei; Research grant / Funding (institution): Daiichi Sankyo; Research grant / Funding (institution): Janssen. All other authors have declared no conflicts of interest.